Literature DB >> 19430954

Vasculogenesis in infantile hemangioma.

Elisa Boscolo1, Joyce Bischoff.   

Abstract

Infantile hemangioma is a vascular tumor that occurs in 5-10% of infants of European descent. A defining feature of infantile hemangioma is the dramatic growth and development into a disorganized mass of blood vessels. Subsequently, a slow spontaneous involution begins around 1 year of age and continues for 4-6 years. The growth and involution of infantile hemangioma is very different from other vascular tumors and vascular malformations, which do not regress and can occur at any time during childhood or adult life. Much has been learned from careful study of the tissue morphology and gene expression patterns during the life-cycle of hemangioma. Tissue explants and tumor-derived cell populations have provided further insight to unravel the cellular and molecular basis of infantile hemangioma. A multipotent progenitor cell capable of de novo blood vessel formation has been isolated from infantile hemangioma, which suggests that this common tumor of infancy, long considered to be a model for pathologic angiogenesis, may also represent pathologic vasculogenesis. Whether viewed as angiogenesis or vasculogenesis, infantile hemangioma represents a vascular perturbation during a critical period of post-natal growth, and as such provides a unique opportunity to decipher mechanisms of human vascular development.

Entities:  

Mesh:

Year:  2009        PMID: 19430954      PMCID: PMC2810616          DOI: 10.1007/s10456-009-9148-2

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  79 in total

1.  Proliferation and apoptosis within juvenile capillary hemangiomas.

Authors:  A J Mancini; B R Smoller
Journal:  Am J Dermatopathol       Date:  1996-10       Impact factor: 1.533

2.  Monocyte chemoattractant protein-1 mRNA expression in hemangiomas and vascular malformations.

Authors:  F F Isik; R P Rand; J S Gruss; D Benjamin; C E Alpers
Journal:  J Surg Res       Date:  1996-02-15       Impact factor: 2.192

3.  Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis.

Authors:  C Suri; P F Jones; S Patan; S Bartunkova; P C Maisonpierre; S Davis; T N Sato; G D Yancopoulos
Journal:  Cell       Date:  1996-12-27       Impact factor: 41.582

4.  Vascular endothelial growth factor confers a growth advantage in vitro and in vivo to stromal cells cultured from neonatal hemangiomas.

Authors:  M Berard; S Sordello; N Ortega; J L Carrier; N Peyri; M Wassef; N Bertrand; O Enjolras; L Drouet; J Plouet
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

5.  Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

Authors:  M S O'Reilly; T Boehm; Y Shing; N Fukai; G Vasios; W S Lane; E Flynn; J R Birkhead; B R Olsen; J Folkman
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

6.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium.

Authors:  G H Fong; J Rossant; M Gertsenstein; M L Breitman
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

7.  E-selectin is present in proliferating endothelial cells in human hemangiomas.

Authors:  B M Kräling; M J Razon; L M Boon; D Zurakowski; C Seachord; R P Darveau; J B Mulliken; C L Corless; J Bischoff
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

8.  Infantile (juvenile) capillary hemangioma: a tumor of heterogeneous cellular elements.

Authors:  B R Smoller; D B Apfelberg
Journal:  J Cutan Pathol       Date:  1993-08       Impact factor: 1.587

9.  Cellular markers that distinguish the phases of hemangioma during infancy and childhood.

Authors:  K Takahashi; J B Mulliken; H P Kozakewich; R A Rogers; J Folkman; R A Ezekowitz
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

10.  Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

Authors:  R A Ezekowitz; J B Mulliken; J Folkman
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

View more
  45 in total

Review 1.  Infantile hemangioma-mechanism(s) of drug action on a vascular tumor.

Authors:  Shoshana Greenberger; Joyce Bischoff
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 2.  Stem cells and the vasculature.

Authors:  Victoria L Bautch
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

3.  JAGGED1 signaling regulates hemangioma stem cell-to-pericyte/vascular smooth muscle cell differentiation.

Authors:  Elisa Boscolo; Camille L Stewart; Shoshana Greenberger; June K Wu; Jennifer T Durham; Ira M Herman; John B Mulliken; Jan Kitajewski; Joyce Bischoff
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-07-14       Impact factor: 8.311

4.  Infantile hemangiomas: A review.

Authors:  Alison B Callahan; Michael K Yoon
Journal:  Saudi J Ophthalmol       Date:  2012-05-23

Review 5.  Blood and lymphatic vessel formation.

Authors:  Victoria L Bautch; Kathleen M Caron
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-03-02       Impact factor: 10.005

6.  VEGFR-1 mediates endothelial differentiation and formation of blood vessels in a murine model of infantile hemangioma.

Authors:  Elisa Boscolo; John B Mulliken; Joyce Bischoff
Journal:  Am J Pathol       Date:  2011-09-21       Impact factor: 4.307

7.  Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells.

Authors:  Xiaorong Ma; Tinghui Zhao; Tianxiang Ouyang; Shujia Xin; Yueting Ma; Mengling Chang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

8.  Hypothesis: the metastatic niche theory can elucidate infantile hemangioma development.

Authors:  Martin C Mihm; J Stuart Nelson
Journal:  J Cutan Pathol       Date:  2010-04       Impact factor: 1.587

Review 9.  Vascular anomalies: from genetics toward models for therapeutic trials.

Authors:  Melanie Uebelhoer; Laurence M Boon; Miikka Vikkula
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

10.  Pharmacological targeting of β-adrenergic receptor functions abrogates NF-κB signaling and MMP-9 secretion in medulloblastoma cells.

Authors:  Borhane Annabi; Eric Vaillancourt-Jean; Alexander G Weil; Richard Béliveau
Journal:  Onco Targets Ther       Date:  2010-11-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.